The Exchange had sought clarification from Sun Pharma Advanced Research Company Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. The company has not submitted declaration in case of unmodified opinion(s) The response of the Company is enclosed.
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SPARC responded to NSE's query about its Q4 FY25 results filing under SEBI LODR Regulation 33, where the exchange had flagged that the company did not submit a declaration regarding unmodified auditor opinion. The company clarified that it had indeed submitted the declaration through its XBRL filing as well as in the board meeting outcome dated May 19, 2025, confirming S R B C & Co LLP issued an unmodified opinion. The same board meeting also approved plans to raise up to Rs. 1,800 crore through securities in one or more tranches (subject to shareholder approval), and appointed Ms. Rekha Warriar and Mr. Venkateswarlu Jasti as independent directors, while re-appointing Mr. Anilkumar Raghavan as CEO for five years. For FY25, standalone revenue from operations stood at Rs. 71.77 crore and net loss narrowed to Rs. 345.22 crore from Rs. 388.11 crore in FY24, with a loss per share of Rs. 10.64. The company continues to rely on promoter group support for its going concern status.
This is a routine procedural clarification with no penalty or adverse regulatory action against the company. However, the proposed Rs. 1,800 crore fundraise plan signals potential equity dilution, which may concern existing shareholders; stock price reaction will depend on the mode (debt vs equity) finally chosen at the AGM.